Immunological signaling during herpes simplex virus-2 and cytomegalovirus vaginal shedding after initiation of antiretroviral treatment

Open Forum Infectious Diseases

Volumn 3, Issue 2, 2016, Pages

  Nason, Martha C ^a   Patel, Eshan U ^a   Kirkpatrick, Allison R ^a   Prodger, Jessica L ^a   Shahabi, Kamnoosh ^b   Tobian, Aaron A R ^c,d   Gianella, Sara ^f   Kalibbala, Sarah ^g   Ssebbowa, Paschal ^g   Kaul, Rupert ^b   Gray, Ronald H ^d,g   Quinn, Thomas C ^a,e   Serwadda, David ^g,h   Reynolds, Steven J ^a,e,g   Redd, Andrew D ^a,e  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b UNIVERSITY OF TORONTO   (Canada)

^c JOHNS HOPKINS HOSPITAL   (United States)

^d JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^e JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g RAKAI HEALTH SCIENCES PROGRAM   (Uganda)

^h MAKERERE UNIVERSITY   (Uganda)

Author keywords

CMV; Cytokine; HIV; HSV 2; Viral shedding

Indexed keywords

ACICLOVIR; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 10; INTERLEUKIN 12P70; INTERLEUKIN 13; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 6; INTERLEUKIN 8; PLACEBO; TUMOR NECROSIS FACTOR;

ADULT; ANTIVIRAL THERAPY; CD4 LYMPHOCYTE COUNT; CONTROLLED STUDY; CYTOMEGALOVIRUS; DISEASE COURSE; DOUBLE BLIND PROCEDURE; FEMALE; HERPES SIMPLEX VIRUS 2; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNITY; LIMIT OF DETECTION; MAJOR CLINICAL STUDY; NOTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; REAL TIME POLYMERASE CHAIN REACTION; TREATMENT OUTCOME; VAGINA; VIRAL LOAD TESTING; VIRUS REACTIVATION; VIRUS SHEDDING;

EID: 84995543245     PISSN: None     EISSN: 23288957     Source Type: Journal    
DOI: 10.1093/ofid/ofw073     Document Type: Note

References (18)

1. Bor J, Herbst AJ, Newell ML, Barnighausen T. Increases in adult life expectancy in rural South Africa: valuing the scale-up of HIV treatment. Science 2013; 339:961-5.
2. French MA, Price P, Stone SF. Immune restoration disease after antiretroviral therapy. AIDS 2004; 18:1615-27.
3. Ratnam I, Chiu C, Kandala NB, Easterbrook PJ. Incidence and risk factors for immune reconstitution inflammatory syndrome in an ethnically diverse HIV type 1-infected cohort. Clin Infect Dis 2006; 42:418-27.
4. Stone SF, Price P, Brochier J, French MA. Plasma bioavailable interleukin-6 is elevated in human immunodeficiency virus-infected patients who experience herpesvirus-associated immune restoration disease after start of highly active antiretroviral therapy. J Infect Dis 2001; 184:1073-7.
5. Barber DL, Andrade BB, Sereti I, Sher A. Immune reconstitution inflammatory syndrome: the trouble with immunity when you had none. Nat Rev Microbiol 2012; 10:150-6.
6. French MA, Lenzo N, John M, et al. Immune restoration disease after the treatment of immunodeficient HIV-infected patients with highly active antiretroviral therapy. HIV Med 2000; 1:107-15.
7. Couppie P, Sarazin F, Clyti E, et al. Increased incidence of genital herpes after HAART initiation: a frequent presentation of immune reconstitution inflammatory syndrome (IRIS) in HIV-infected patients. AIDS Patient Care STDS 2006; 20:143-5.
8. Fife KH, Mugwanya K, Thomas KK, et al. Transient increase in herpes simplex virus type 2 (HSV)-2-associated genital ulcers following initiation of antiretroviral therapy in HIV-1/HSV-2-coinfected individuals. J Infect Dis 2015; 213:1573-8.
9. Reynolds SJ, Makumbi F, Newell K, et al. Effect of daily aciclovir on HIV disease progression in individuals in Rakai, Uganda, co-infected with HIV-1 and herpes simplex virus type 2: a randomised, double-blind placebo-controlled trial. Lancet Infect Dis 2012; 12:441-8.
10. Stone SF, Price P, Keane NM, et al. Levels of IL-6 and soluble IL-6 receptor are increased in HIV patients with a history of immune restoration disease after HAART. HIV Med 2002; 3:21-7.
11. Andrade BB, Singh A, Narendran G, et al. Mycobacterial antigen driven activation of CD14++CD16-monocytes is a predictor of tuberculosis-associated immune reconstitution inflammatory syndrome. PLoS Pathog 2014; 10:e1004433.
12. Worsley CM, Suchard MS, Stevens WS, et al. Multi-analyte profiling of ten cytokines in South African HIV-infected patients with immune reconstitution inflammatory syndrome (IRIS). AIDS Res Ther 2010; 7:36.
13. Tobian AA, Quinn TC. Herpes simplex virus type 2 and syphilis infections with HIV: an evolving synergy in transmission and prevention. Curr Opin HIV AIDS 2009; 4:294-9.
14. Tobian AA, Ssempijja V, Kigozi G, et al. Incident HIV and herpes simplex virus type 2 infection among men in Rakai, Uganda. AIDS 2009; 23:1589-94.
15. Redd AD, Newell K, Patel EU, et al. Decreased monocyte activation with daily acyclovir use in HIV-1/HSV-2 coinfected women. Sex Transm Infect 2015; 91:485-8.
16. Gianella S, Redd AD, Grabowski MK, et al. Vaginal cytomegalovirus shedding before and after initiation of antiretroviral therapy in Rakai, Uganda. J Infect Dis 2015; 212:899-903.
17. Tobian AA, Grabowski MK, Serwadda D, et al. Reactivation of herpes simplex virus type 2 after initiation of antiretroviral therapy. J Infect Dis 2013; 208:839-46.
18. French MA, Cozzi-Lepri A, Arduino RC, et al. Plasma levels of cytokines and chemokines and the risk of mortality in HIV-infected individuals: a case-control analysis nested in a large clinical trial. AIDS 2015; 29:847-51.